No Difference in Outcomes and Treatment No Matter the Etiology—Analysis from PARADIGM-HF Trial

No Difference in Outcomes and Treatment No Matter the Etiology—Analysis from PARADIGM-HF Trial Posted By:
...

Heart failure (HF) is a complicated disease state with multiple, staged therapies. Over the last couple of years, addition of a sacubitril/valsartan combination has been shown to improve HF symptoms and reduce hospitalizations. This improvement has been a welcome addition to the multi-faceted approach for those with HF with reduced ejection fraction (HFrEF), and has been added to the 2017 updated American Heart Association/American College of Cardiology regimen for treatment of HF.

Because the disease has multiple etiologies, the PARADIGM-HF trial was conducted to analyze the outcomes and effects of sacubitril/valsartan use based on the etiology of the HF. Of the 8399 patients studied, 60% (5036) had an ischemic etiology while the remaining 40% (1595) had a variety of non-ischemic conditions, such as hypertension and other diseases (viral, infectious, alcoholic, valvular, diabetes, and idiopathic). The findings suggest that there is no difference in outcomes and effects when using sacubitril/valsartan, regardless of the type of HFrEF the subjects had; In other words, the medication proved to be effective regardless of the etiology. The study's primary end points evaluated hospitalizations and death from any cause; the results make the drug favored over enalapril for the treatment of HFrEF.

The bottom line for primary care practitioners and those treating HFrEF is clear: when caring for patients with HFrEF and a New York Heart Association Class II-IV, the use of sacubitril/valsartan will improve outcomes and efficacy and should be used as part of the normal regimen. Physician assistants and nurse practitioners would benefit from keeping up with the current literature to ensure the best outcomes for this patient population.

Reference
  • Balmforth C, Simpson J, Shen L, et al. Outcomes and effect of treatment according to etiology in HFrEF: an analysis of PARADIGM-HF. JACC Heart Fail. 2019;7:457-465.

Share

Filed under: Cardiometabolic

Related
Phase III FLOW Trial Results Establishes Semaglutide’s Role in Treating T2D and CKD

Phase III FLOW Trial Results Establishes Semagluti ...

The highly anticipated results of the FLOW (Evaluate Renal Function with Semaglutide Once Weekly) tr ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading
The Gift of Time and Key Connection Between Diabetes Mellitus and Autoimmune Disorders

The Gift of Time and Key Connection Between Diabet ...

Are you aware that approximately 64,000 Americans are diagnosed with type 1 diabetes (T1D) each year ...

Filed under: Cardiometabolic


Continue Reading
The Importance of Shared Decision-making in Obesity

The Importance of Shared Decision-making in Obesit ...

Many areas of healthcare are starting to talk about the importance of shared decision-making (SDM), ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading
Addressing ASCVD Risk in HIV: An Update to the DHHS HIV Guidelines

Addressing ASCVD Risk in HIV: An Update to the DHH ...

The incidence of atherosclerotic cardiovascular disease (ASCVD) is estimated to be twice as high in ...

Filed under: Infectious Diseases, Preventive Medicine, Public Health, Cardiometabolic, NPs & PAs


Continue Reading
Understanding the Multifactorial Etiology of Obesity and the Metabolic Adaptations to Weight Loss

Understanding the Multifactorial Etiology of Obesi ...

Obesity Causes Overeating, Not the Other Way AroundOne of my favorite quotes from Dr Lee Kaplan is, ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading
Atrial Fibrillation: Optimizing Outcomes by Addressing Social Determinants of Health and Implicit Bias

Atrial Fibrillation: Optimizing Outcomes by Addres ...

Atrial fibrillation (AF) is the most common sustained arrhythmia diagnosed, and its prevalence is ex ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading